ArticleHuman mutation2026
A Pan-Cancer Atlas of TIPE2 Identifies Its Association With the Tumor Immune Microenvironment, Prognosis, and Immunotherapeutic Potential.
Article in Human mutation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A Pan-Cancer Atlas of TIPE2 Identifies Its Association With the Tumor Immune Microenvironment, Prognosis, and Immunotherapeutic Potential.Human mutation · 2026Article
- TIPE3 in Cancer: A Multifaceted Regulator of Tumorigenesis, Therapeutic Resistance, and Clinical Outcomes.Technology in cancer research & treatmentReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The tumor microenvironment (TME) plays a pivotal role in tumorigenesis, progression, and metastasis. Tumor necrosis factor alpha-induced protein 8-like 2 (TNFAIP8L2; TIPE2), a member of the TIPE family, is a key regulator of immune homeostasis. In this study, we comprehensively characterized the pan-cancer landscape of TIPE2 and evaluated its potential significance for prognosis and immunotherapy-related stratification. Using multiomics data from public databases such as TCGA, GTEx, and HPA, we systematically analyzed TIPE2 expression patterns, genetic and epigenetic alterations, and their associations with clinical outcomes and immune characteristics across 33 cancer types. TIPE2 was found to be enriched in immune cells and frequently dysregulated in tumors compared with normal tissues. TIPE2 expression demonstrated a significant correlation with the infiltration of various immune cell populations across most cancers and exhibited strong associations with the expression of immune checkpoint genes. Alterations in TIPE2, along with aberrant methylation, were identified in a subset of tumors, indicating multilayered regulatory mechanisms. Gene set enrichment analysis further demonstrated that elevated TIPE2 expression is associated with immune-related pathways. Survival analyses demonstrated that TIPE2 expression was associated with overall survival and disease-free survival across multiple cancer types, exhibiting directionally heterogeneous effects depending on tumor context. Collectively, these findings identify TIPE2 as an immune-relevant biomarker candidate with prognostic significance across various cancers and warrant further mechanistic and clinical validation to elucidate its potential role in immunotherapy-based patient stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.